Regulatory non compliance costs the pharma industry billions in fines, audits and much more each year. To avoid these fines and bad reputation pharma companies rely heavily on their compliance teams, who provide oversight from R&D to the very end of a product cycle.
Industry representatives share what they find the biggest challenges they face in their day to day work. They also give insight and thoughts on the implications and how to overcome them.
•Britta Luescher, Compliance Director, Novartis International AG
•Dr. Michael Bartke, Director Compliance, Daiichi Sankyo
•Ana Gonzalez Prada, EMEA Corporate Counsel, Ethics & Compliance, Baxter Healthcare
•Nick Broughton, Managing Director, Pharmaceuticalethics.com
•Dr. Wolfgang Beck, Associate Partner, WMQMS Ltd.
•Niklas Pieper, Senior Corporate Compliance Counsel, Bayer Healthcare
